Wall Street Zen Upgrades Century Therapeutics (NASDAQ:IPSC) to “Hold”

Century Therapeutics (NASDAQ:IPSC) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Saturday, Wall Street Zen reports.

IPSC has been the subject of a number of other reports. Mizuho began coverage on shares of Century Therapeutics in a research note on Wednesday, May 27th. They set an “outperform” rating and a $8.00 target price for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Century Therapeutics in a report on Thursday, July 2nd. Four equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $4.75.

Century Therapeutics Price Performance

Shares of NASDAQ IPSC opened at $1.94 on Friday. The firm’s 50-day moving average price is $2.10 and its 200-day moving average price is $2.23. Century Therapeutics has a 52-week low of $0.43 and a 52-week high of $3.04. The company has a market cap of $351.28 million, a PE ratio of -2.09 and a beta of 1.59.

Century Therapeutics (NASDAQ:IPSC) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.06). As a group, equities research analysts anticipate that Century Therapeutics will post -0.51 EPS for the current fiscal year.

Institutional Trading of Century Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Prudential Financial Inc. purchased a new position in shares of Century Therapeutics during the 2nd quarter valued at about $25,000. Bank of New York Mellon Corp bought a new position in shares of Century Therapeutics during the 1st quarter valued at approximately $29,000. Qube Research & Technologies Ltd purchased a new stake in Century Therapeutics in the 2nd quarter worth approximately $38,000. Quadrant Private Wealth Management LLC increased its holdings in Century Therapeutics by 31.0% in the 1st quarter. Quadrant Private Wealth Management LLC now owns 20,022 shares of the company’s stock worth $45,000 after acquiring an additional 4,736 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new stake in Century Therapeutics during the 2nd quarter worth approximately $51,000. Hedge funds and other institutional investors own 50.20% of the company’s stock.

Century Therapeutics Company Profile

Century Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of allogeneic cell therapies for cancer. Utilizing induced pluripotent stem cell (iPSC) technology, the company engineers “off-the-shelf” natural killer (NK) and T cell candidates designed to target hematologic malignancies and solid tumors. By harnessing iPSC-derived immune cells, Century aims to overcome challenges associated with patient-derived therapies, such as manufacturing variability and treatment delays.

The company’s proprietary platform integrates gene editing, synthetic biology and scalable cell expansion processes to generate a pipeline of product candidates.